Ann: BCAL to Host Investor Webcast, page-20

Prediction. Fast forward this time next year.
These threads will be over run with massive market discovery.
Wont be space to to breath quietly.

Fast forward 5 years. Assume having launched commercial in AUS late 2024, and USA 2025, the volumes market assume to garnished significant momentum and size => mega cash cow.

Clever to launch with mams, as support synergy.
At what point, then do the tests escape the orbit of the Mams ?
(especially then for those outside of the mams screening, as cancers risk to younger populations.)

A product, with an existing customer base, but with the expansion of a massive general test, hopefully detects well before the current standard of care, to identify a lump by hand. / before you can warrant approval to get an ultrasound or MRI.

When the standard of care changes to vastly improve the early detection outcomes, the volumes of tests may reach the skies. = volumes x margins = $$$$

Multi billion dollar valuation achievable imo should all go well.
If they are able to extend the IP to other cancer types.,,,++ $$$$